Search results for: James J. Collins | Wyss Institute

Wyss Institute Search Site

Technologies 10

AminoX: Making Biologics Safer with Synthetic Biology and Advanced Chemistry
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition.
Sugar-to-Fiber Enzyme for Healthier Food
In collaboration with Kraft Heinz, our sugar-to-fiber product can convert sugar in food products into prebiotic fiber in the human gut, reducing the amount of sugar absorbed into the bloodstream without altering the amount of sugar in existing food product recipes.
Sparkle: Instant Biosensors for Real-Time Imaging
Sparkle is revolutionizing the binder assay industry by harnessing novel chemistry to create instant fluorescent biosensors for a wide variety of uses.
Engineered Live Biotherapeutic Product (eLBP) to Protect the Microbiome from Antibiotics
eLBP is a safe and cost-effective therapeutic for patients treated with beta-lactam antibiotics that safeguards against the loss of health-essential microbes while preventing the development and spread of antibiotic resistance.
wFDCF Face Masks: A Wearable COVID-19 Diagnostic
The Problem The COVID-19 pandemic has made it starkly clear that the world lacks rapid, accurate diagnostic tests for pathogens. When patients arrive in a medical facility for treatment, the triage process is hindered by diagnostic tests that are inaccurate or take a long time to produce results. In addition, patients who are asymptomatic and...
INSPECTR™: Direct-to-Consumer Molecular Diagnostic
INSPECTR™ is a molecular diagnostic platform that combines freeze-dried synthetic gene networks with cell-free expression systems to create novel biosensors that detect and report the presence of a target DNA or RNA molecule without the need for power or lab equipment. This technology was licensed by Wyss startup Sherlock Biosciences in 2019.

Collaborations 1

Kraft Heinz Partnership
The Kraft Heinz company approached the Wyss Institute for help to achieve its ambitious goal to make its food products healthier, resulting in a novel technology that is ripe for commercialization.

News 89

Multimedia 19

Events 9